An injected muscle graft that exercises itself, tested in mice

Researchers at the Chinese Academy of Sciences’ Institute of Zoology reported in Nature Aging on 26 August 2026 that a single subcutaneous injection of muscle cells caused the cells to self-assemble into vascularised skeletal muscle grafts that contract continuously without any movement by the animal. They call them myografts.

In aging and obese mouse models the grafts raised whole-body muscle mass and function and moved a set of measures well outside the implant site: bone density, endurance, liver function, and cognitive performance. The mice also showed lower white-blood-cell counts and triglycerides, less liver damage, and higher energy expenditure than controls. A separate result treats the graft as an in-body factory: virally transduced myografts produced sustained therapeutic proteins, including parathyroid hormone, growth hormone and GLP-1, without observed side effects.

Principal investigator Ng Shyh-Chang described the goal as isolating the useful part of exercise while avoiding its load on the heart and joints. The authors state plainly that the safety and pharmacological profile of autologous myografts remains to be established in human trials, and none have begun. What has been shown is that a localised, self-contracting implant can produce a systemic effect in mice — the mechanism, not the therapy.